Penn Medicine Researchers Are Developing a Blood Test for Those at Highest Risk of Kidney Disease
Researchers are developing a blood test to better predict the risk of kidney disease in Black Americans who carry high-risk APOL1 gene variants.
Penn Medicine’s Virginia Lee to Retire after Prolific Career
She leaves behind a lasting legacy in brain disease research, with discoveries that are drastically transforming the scientific understanding of diseases like Alzheimer's Disease and ALS.
New Clinical Data Move Cabaletta Closer to First Autoimmune CAR-T Approval
The company reported encouraging clinical data for its CAR T-cell therapy, RESE-CEL™.
Vivodyne and Opus Genetics Named Most Innovative Biotech Companies of 2026 by Fast Company
The companies are spun out of Penn Engineering and Penn Medicine, respectively.
GemmaBio Joins Lilly Gateway Labs as First Tenant
GemmaBio was co-founded by Penn Medicine Emeritus Professor James M. Wilson, MD, PhD.
Ascidian Therapeutics and Eli Lilly Establish Global Research Partnership
Ascidian was founded with technology developed by Jean Bennett, MD, PhD.
Penn Scientist Elected President of Leading Cancer Organization
In this role, he aims to advance innovation in cancer treatment and prevention.
NIH Director Jay Bhattacharya and Senator Dave McCormick Visit Penn Medicine
The visit included meetings with researchers, clinicians, and innovators at Penn and a tour of one of Penn’s CAR T cell laboratories.
Ultragenyx Reports Promising Phase III Clinical Trial Results for Urea Cycle Disorder Treatment
Ultragenyx’s gene therapy DTX301, based on technology invented by Jim Wilson, MD, PhD, Emeritus Professor at Penn Medicine, helped control ammonia levels in patients with a urea cycle disorder.
Verismo Therapeutics Receives $28 million to Accelerate KIR-CAR Clinical Development
The funding from HLB Innovation, Verismo’s parent company, will advance clinical development of its killer cell immunoglobulin-like receptor (KIR)-chimeric antigen receptor (CAR) platform\.